“Wolverine (bpc 5mg, tb500 5mg)” has been added to your cart. View cart
CJC 1295 No DAC + IPA 10mg
Home
CJC 1295 No DAC + IPA 10mg
Rated 4.3 out of 5
CJC 1295 No DAC + IPA 10mg
$70.00
🧬 Chemical Overview
CJC-1295 No DAC
Common Name
CJC-1295 No DAC (Modified GRF 1-29)
Molecular Weight
3367.97 g/mol
CAS Number
863288-34-0
Half-Life (research)
~30 min (vs. ~2 min for native GHRH)
Physical Form
Lyophilized Powder
Purity
≥98% (HPLC + LC-MS verified)
Ipamorelin (co-supplied)
Common Name
Ipamorelin (IPA)
Molecular Formula
C₃₈H₄₉N₉O₅
Molecular Weight
711.85 g/mol
CAS Number
170851-70-4
Half-Life (research)
~2 hours
Physical Form
Lyophilized Powder, separate vial
Purity
≥98% (HPLC + LC-MS verified)
ℹ️ Supplied as two separate lyophilized vials for dual-stimulation GHRH/ghrelin-axis research protocols.
⚗️ Mechanism of Action
Mechanism of Action
CJC-1295 No DAC is a synthetic analogue of GHRH(1-29), modified at four amino acid positions to resist DPP-IV enzymatic cleavage. It selectively binds the GHRH receptor on pituitary somatotroph cells, stimulating intracellular cAMP via Gαs-coupled signaling and driving pulsatile growth hormone (GH) secretion.
Ipamorelin acts via selective agonism of GHS-R1a (ghrelin receptor) through a Gαq-coupled IP3/DAG pathway, independent of the GHRH receptor. Noted in research for minimal effect on cortisol and prolactin secretion compared to earlier GH secretagogues.
When studied in combination, the two peptides produce additive or synergistic GH secretory responses by engaging both the GHRH-axis and ghrelin-axis simultaneously. Downstream, GH drives hepatic IGF-1 production via JAK2-STAT5 signaling, with IGF-1 acting through the IGF-1R/PI3K/Akt/mTOR pathway.
📋 Research Applications
Research Applications
GHRH receptor activation and pituitary GH secretion studies
GHS-R1a (ghrelin receptor) agonism research (Ipamorelin component)
Dual-axis GHRH/ghrelin synergy protocols in pituitary research models
IGF-1 axis and downstream PI3K/Akt/mTOR signaling studies
Pulsatile GH secretion pattern investigation
DPP-IV stability and peptide half-life modification research
📖 Peer-Reviewed References
Peer-Reviewed References
Jetté L, et al. hGRF(1-29)-Albumin Bioconjugates: CJC-1295 as a Long-Lasting GRF Analog. Endocrinology. 2005;146(7):3052–3058.
Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561.
Veldhuis JD, et al. Dual secretagogue drive of burst-like growth hormone secretion. J Clin Endocrinol Metab. 2001;86(12):5955–5963.
🧪 Testing & COA
Testing & Supply Specifications
Every Blueprint Labs batch is independently verified by third-party analytical laboratories prior to release. Identity and purity confirmed via HPLC and mass spectrometry. Full batch records maintained for chain-of-custody traceability.
Research Use Only. This product is intended strictly for laboratory and in vitro research purposes. Not for human consumption, veterinary use, or any clinical application. Not intended to diagnose, treat, cure, or prevent any disease or medical condition. All statements are informational and have not been evaluated by the FDA.
